FSH and folliculogenesis: From physiology to ovarian stimulation

Reproductive BioMedicine Online

Volumn 12, Issue 6, 2006, Pages 684-694

  Vegetti, Walter ^a   Alagna, Federica ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Assisted reproduction; FSH; LH; Ovarian stimulation; Ovulation induction; Physiology

Indexed keywords

CETRORELIX; CHORIONIC GONADOTROPIN; FOLLITROPIN; FOLLITROPIN RECEPTOR; GANIRELIX; GLYCOPROTEIN; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; HORMONE; HUMAN MENOPAUSAL GONADOTROPIN; LONG ACTING DRUG; LUTEINIZING HORMONE; PEPTIDE; PLACEBO; RECOMBINANT FOLLITROPIN; RECOMBINANT LUTEINIZING HORMONE;

ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CORPUS LUTEUM; DRUG HALF LIFE; DRUG USE; FEMALE; FERTILIZATION; HORMONE STRUCTURE; HUMAN; INFERTILITY THERAPY; ITALY; LUTEINIZING HORMONE RELEASE; MULTIPLE PREGNANCY; OOCYTE MATURATION; OVARY FOLLICLE; OVARY FOLLICLE DEVELOPMENT; OVARY HYPERSTIMULATION; OVULATION; RISK REDUCTION; SINGLE DRUG DOSE; STEREOCHEMISTRY;

EID: 33745032129     PISSN: 14726483     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1472-6483(10)61080-2     Document Type: Article

References (104)

1. Albano C, Felberbaum RE, Smitz J et al. 2000 Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. European Cetrorelix Study Group. Human Reproduction 15, 526-531.
2. Al-Inany H, Aboulghar M 2002 GnRH antagonist in assisted reproduction: a Cochrane review. Human Reproduction 17, 874-885.
3. Al-Inany H, Aboulghar M, Mansour R et al. 2003 Meta-analysis of recombinant versus urinary-derived FSH: an update. Human Reproduction 18, 305-313.
4. Balasch J, Fábregues F, Peñarrubia J et al. 2004 Outcome from consecutive assisted reproduction cycles in patients treated with recombinant follitropin alfa filled-by-bioassay and those treated with recombinant follitropin alfa filled-by-mass. Reproductive BioMedicine Online 8, 408-413.
5. Balen AH, Mulders AG, Fauser BC et al. 2002 Pharmacodynamics of a single low dose of long-acting recombinant follicle-stimulating hormone (FSH-carboxy terminal peptide, corifollitropin alfa) in women with World Health Organization group II anovulatory infertility. Journal of Clinical Endocrinology and Metabolism 89, 6297-6304.
6. Bassett RM, Driebergen R 2005 Continued improvements in the quality and consistency of follitropin alfa, recombinant human FSH. Reproductive BioMedicine Online 10, 169-177.
7. Beckers NG, Macklon NS, Devroey P et al. 2003 First live birth after ovarian stimulation using a chimeric long-acting human recombinant follicle-stimulating hormone (FSH) agonist (recFSH-CTP) for in vitro fertilization. Fertility and Sterility 79, 621-623.
8. Behre HM, Greb RR, Mempel A et al. 2005 Significance of a common single nucleotide polymorphism in exon 10 of the follicle-stimulating hormone (FSH) receptor gene for the ovarian response to FSH: a pharmacogenetic approach to controlled ovarian hyperstimulation. Pharmacogenetics and Genomics 15, 451-456.
9. Boothby M, Ruddon RW, Anderson C 1981 A single gonadotropin alpha-subunit gene in normal tissue and tumor-derived cell lines. Journal of Biological Chemistry 256, 5121-5127.
10. Borm G, Mannaerts B 2000 Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. The European Orgalutran Study Group. Human Reproduction 15, 1490-1498.
11. Bouchard P, Fauser BC 2000 Gonadotropin-releasing hormone antagonist: new tools vs. old habits. Fertility and Sterility 73, 18-20.
12. Bouloux PM, Handelsman DJ, Jockenhovel F et al. 2001 FSH-CTP study group. First human exposure to FSH-CTP in hypogonadotrophic hypogonadal males. Human Reproduction 16, 1592-1597.
13. Bristow RE, Karlan BY 1996 The risk of ovarian cancer after treatment for infertility. Current Opinion in Obstetrics and Gynecology 8, 32-37.
14. Brown JB 1978 Pituitary control of ovarian function - concepts derived from gonadotrophin therapy. Australian and New Zealand Journal of Obstetrics and Gynaecology 18, 46-54.
15. Campbell BK, Dobson H, Baird DT, Scaramuzzi RJ 1999 Examination of the relative role of FSH and LH in the mechanism of ovulatory follicle selection in sheep. Journal of Reproduction and Fertility 117, 355-367.
16. Choi YM, Yoon JS, Hwang KR et al. 2004 Follicle-stimulating hormone receptor polymorphism and ovarian responses to controlled ovarian hyperstimulation for IVF-ET. Fertility and Sterility 82, S206-S207.
17. Chung K, Krey L, Katz J, Noyes N 2005 Evaluating the role of exogenous luteinizing hormone in poor responders undergoing in vitro fertilization with gonadotropin-releasing hormone antagonists. Fertility and Sterility 84, 313-318.
18. Daya S 2002 Updated meta-analysis of recombinant follicle-stimulating hormone (FSH) versus urinary FSH for ovarian stimulation in assisted reproduction. Fertility and Sterility 77, 711-714.
19. de Mouzon J, Allavena E, Schmitt C et al. 2004 In vitro fertilization in France: economic aspects and influence of the gonadotropin choice (urinary vs. recombinant) on cost. Gynecologie Obstetrique et Fertilité 32, 508-518.
20. De Placido G, Alviggi C, Perino A et al. 2005 Italian Collaborative Group on Recombinant Human Luteinizing Hormone. Recombinant human LH supplementation versus recombinant human FSH (rFSH) step-up protocol during controlled ovarian stimulation in normogonadotrophic women with initial inadequate ovarian response to rFSH. A multicentre, prospective, randomized controlled trial. Human Reproduction 20, 390-396.
21. Deutsches IVF Register 2002 Annual report from the Germany IVF Registry 2002, http://www.deutsches-ivf-register.de.
22. Devroey P, Fauser BC, Platteau P et al. 2004. Induction of multiple follicular development by a single dose of long-acting recombinant follicle-stimulating hormone (FSH-CTP, corifollitropin alfa) for controlled ovarian stimulation before in vitro fertilization. Journal of Clinical Endocrinology and Metabolism 89, 2062-2070.
23. Devroey P, Tournaye H, Van Steirteghem A et al. 1998 The use of a 100 IU starting dose of recombinant follicle stimulating hormone (Puregon) in in-vitro fertilization. Human Reproduction 13, 565-566.
24. Dias JA, Lindau-Shepard B, Hauer C, Auger I 1998 Human follicle-stimulating hormone structure-activity relationships. Biology of Reproduction 58, 1331-1336.
25. Dorn C 2005 FSH: what is the highest dose for ovarian stimulation that makes sense on an evidence-based level? Reproductive BioMedicine Online 11, 555-561.
26. Driebergen R, Baer G 2003 Quantification of follicle stimulating hormone (follitropin alfa): is in-vivo bioassay still relevant in the recombinant age? Current Medical Research and Opinion 19, 41-46.
27. Duijkers IJ, Klipping C, Boerrigter PJ et al. 2002 Single dose pharmacokinetics and effects on follicular growth and serum hormones of a long-acting recombinant FSH preparation (FSH-CTP) in healthy pituitary-suppressed females. Human Reproduction 17, 1987-1993.
28. Emperaire JC 2005 Respective efficacy of gonadotrophins should be the heart of the debate. Reproductive BioMedicine Online 11, 540-542.
29. Engel JB, Riethmuller-Winzen H, Diedrich K 2005 Extrapituitary effects of GnRH antagonists in assisted reproduction: a review. Reproductive BioMedicine Online 10, 230-234.
30. European and Middle East Orgalutran Study Group 2001 Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation. Human Reproduction 16, 644-651.
31. Falconer H, Andersson E, Aanesen A et al. 2005 Follicle-stimulating hormone receptor polymorphisms in a population of infertile women. Acta Obstetricia et Gynecologica Scandinavica 84, 806-811.
32. Fan QR, Hendrickson WA 2005 Structure of human follicle-stimulating hormone in complex with its receptor. Nature 433, 269-277.
33. Fares FA, Suganuma N, Nishimori K et al. 1992. Design of a long-acting follitropin agonist by fusing the C-terminal sequence of the chorionic gonadotropin beta subunit to the follitropin beta subunit. Proceedings of the National Academy of Sciences of the United States of America 89, 4304-4308.
34. Fauser BC, Van Heusden AM 1997 Manipulation of human ovarian function: physiological concepts and clinical consequences. Endocrine Reviews 18, 71-106.
35. Felberbaum R, Griesinger G, Finas D et al. 2005 To agonize or antagonize in gonadotrophin stimulation cycles? Reproductive BioMedicine Online 10 (Suppl. 3), 33-36.
36. Felberbaum R, Reissmann T, Kupker W et al. 1996 Hormone profiles under ovarian stimulation with human menopausal gonadotropin (hMG) and concomitant administration of the gonadotropin releasing hormone (GnRH)-antagonist Cetrorelix at different dosages. Journal of Assisted Reproduction and Genetics 13, 216-222.
37. Feldman B, Seidman DS, Levron J et al. 2001 In vitro fertilization following natural cycles in poor responders. Gynecological Endocrinology 15, 328-334.
38. Ferraretti AP, Gianaroli L, Magli MC et al. 2004 Exogenous luteinizing hormone in controlled ovarian hyperstimulation for assisted reproduction techniques. Fertility and Sterility 82, 1521-1526.
39. Fiddes JC, Goodman HM 1979 Isolation, cloning and sequence analysis of the cDNA for the alpha-subunit of human chorionic gonadotropin. Nature 281, 351-356.
40. Filicori M, Cognigni GE, Tabarelli C et al. 2002 Stimulation and growth of antral ovarian follicles by selective LH activity administration in women. Journal of Clinical Endocrinology and Metabolism 87, 1156-1161.
41. Filicori M, Cognigni GE, Taraborrelli S et al. 2001 Luteinizing hormone activity in menotropins optimizes folliculogenesis and treatment in controlled ovarian stimulation. Journal of Clinical Endocrinology and Metabolism 86, 337-343.
42. Fox KM, Dias JA, Van Roey P 2001 Three-dimensional structure of human follicle-stimulating hormone. Molecular Endocrinology 15, 378-389.
43. Glasier A, Thatcher SS, Wickings EJ et al. 1988 Superovulation with exogenous gonadotropins does not inhibit the luteinizing hormone surge. Fertility and Sterility 49, 81-85.
44. Goff AK, Armstrong DT 1977 Stimulatory action of gonadotropins and prostaglandins on adenosine-3′,5′-monophosphate production by isolated rat granulosa cells. Endocrinology 101, 1461-1467.
45. Gougeon A 1996 Regulation of ovarian follicular development in primates: facts and hypotheses. Endocrine Reviews 17, 121-155.
46. Greb RR, Grieshaber K, Gromoll J et al. 2005a A common single nucleotide polymorphism in exon 10 of the human follicle stimulating hormone receptor is a major determinant of length and hormonal dynamics of the menstrual cycle. Journal of Clinical Endocrinology and Metabolism 90, 4866-4872.
47. Greb RR, Behre HM, Simoni M 2005b Pharmacogenetics in ovarian stimulation-current concepts and future options. Reproductive BioMedicine Online 11, 589-600.
48. Griesinger G, Schultze-Mosgau A, Dafopoulos K et al. 2005a Recombinant luteinizing hormone supplementation to recombinant follicle-stimulating hormone induced ovarian hyperstimulation in the GnRH-antagonist multiple-dose protocol. Human Reproduction 20, 1200-1206.
49. Griesinger G, Felberbaum R, Diedrich K 2005b GnRH antagonists in ovarian stimulation: a treatment regimen of clinicians' second choice? Data from the German national IVF registry. Human Reproduction 20, 2373-2375.
50. Hugues JN, Barlow DH, Rosenwaks Z et al. 2003 Improvement in consistency of response to ovarian stimulation with recombinant human follicle stimulating hormone resulting from a new method for calibrating the therapeutic preparation. Reproductive BioMedicine Online 6, 185-190.
51. Klein J, Lobel L, Pollak S et al. 2003 Development and characterization of a long-acting recombinant hFSH agonist. Human Reproduction 18, 50-56.
52. Klein J, Lobel L, Pollak S et al. 2002 Pharmacokinetics and pharmacodynamics of single-chain recombinant human follicle-stimulating hormone containing the human chorionic gonadotropin carboxyterminal peptide in the rhesus monkey. Fertility and Sterility 77, 1248-1255.
53. Kolibianakis EM, Albano C, Kahn J et al. 2003 Exposure to high levels of luteinizing hormone and estradiol in the early follicular phase of gonadotropin-releasing hormone antagonist cycles is associated with a reduced chance of pregnancy. Fertility and Sterility 79, 873-880.
54. Ludwig M, Keck C 2005 Recombinant gonadotrophins in reproductive medicine: gold standard for ovarian stimulation therapy in the 21st century. Reproductive BioMedicine Online 11, 535-536.
55. Ludwig M, Rabe T, Buhlker K et al. 2004 Efficacy of recombinant human FSH in comparison to urinary HMG following a long down-regulation protocol - an analysis of 24,764 ART cycles in Germany. Journal fur Reproduktionmedizin und Endokrinologie 1, 284-288.
56. Ludwig M, Katalinic A, Diedrich K 2001 Use of GnRH antagonists in ovarian stimulation for assisted reproductive technologies compared to the long protocol. Meta-analysis. Archives of Gynecology and Obstetrics 265, 175-182.
57. Ludwig M, Felberbaum RE, Devroey P et al. 2000 Significant reduction of the incidence of ovarian hyperstimulation syndrome (OHSS) by using the LHRH antagonist Cetrorelix (Cetrotide) in controlled ovarian stimulation for assisted reproduction. Archives of Gynecology and Obstetrics 264, 29-32.
58. Marrs R, Meldrum D, Muasher S et al. 2004 Randomized trial to compare the effect of recombinant human FSH (follitropin alfa) with or without recombinant human LH in women undergoing assisted reproduction treatment. Reproductive BioMedicine Online 8, 175-182.
59. Matzuk MM, Hsueh AJ, Lapolt P et al. 1990 The biological role of the carboxyl-terminal extension of human chorionic gonadotropin [corrected] beta-subunit. Endocrinology 126, 376-383.
60. McGee EA, Hsueh AJ 2000 Initial and cyclic recruitment of ovarian follicles. Endocrine Reviews 21, 200-214.
61. Meldrum DR, Rivier J, Garzo G et al. 1994 Successful pregnancies with unstimulated cycle oocyte donation using an antagonist of gonadotropin-releasing hormone. Fertility Sterility 61, 556-557.
62. Messinis IE, Templeton AA 1989 Pituitary response to exogenous LHRH in superovulated women. Journal of Reproduction and Fertility 87, 633-639.
63. Messinis IE, Templeton AA 1987 Endocrine and follicle characteristics of cycles with and without endogenous luteinizing hormone surges during superovulation induction with pulsatile follicle-stimulating hormone. Human Reproduction 2, 11-16.
64. Messinis IE, Loutradis D, Domali E et al. 2005 Alternate day and daily administration of GnRH antagonist may prevent premature luteinization to a similar extent during FSH treatment. Human Reproduction 20, 3192-3197.
65. Miro F, Hillier SG 1996 Modulation of granulosa cell deoxyribonucleic acid synthesis and differentiation by activin. Endocrinology 137, 464-468.
66. Montanelli L, Delbaere A, Di Carlo C et al. 2004 A mutation in the follicle-stimulating hormone receptor as a cause of familial spontaneous ovarian hyperstimulation syndrome. Journal of Clinical Endocrinology and Metabolism 89, 1255-1258.
67. Morgia F, Sbracia M, Schimberni M et al. 2004 A controlled trial of natural cycle versus microdose gonadotropin-releasing hormone analog flare cycles in poor responders undergoing in vitro fertilization. Fertility and Sterility 81, 1542-1547.
68. Ozturk O, Bhattacharya S, Templeton A 2001 Avoiding multiple pregnancies in ART: evaluation and implementation of new strategies. Human Reproduction 16, 1319-1321.
69. Paulson RJ, Sauer MV, Lobo RA 1994 Addition of a gonadotropin releasing hormone (GnRH) antagonist and exogenous gonadotropins to unstimulated in vitro fertilization (IVF) cycles: physiologic observations and preliminary experience. Journal of Assisted Reproduction and Genetics 11, 28-32.
70. Pelinck MJ, Vogel NE, Hoek A et al. 2005 Minimal stimulation IVF with late follicular phase administration of the GnRH antagonist cetrorelix and concomitant substitution with recombinant FSH: a pilot study. Human Reproduction 20, 642-648.
71. Pelinck MJ, Hoek A, Simons AH, Heineman MJ 2002 Efficacy of natural cycle IVF: a review of the literature. Human Reproduction Update 8, 129-139.
72. Perez Mayorga M, Gromoll J, Behre HM et al. 2000 Ovarian response to follicle-stimulating hormone (FSH) stimulation depends on the FSH receptor genotype. Journal of Clinical Endocrinology and Metabolism 85, 3365-3369.
73. Phillips DJ, Albertsson-Wikland K et al. 1997 Changes in the isoforms of luteinizing hormone. Journal of Clinical Endocrinology and Metabolism 82, 3103-3106.
74. Pierce JG, Parsons TF 1981 Glycoprotein hormones: structure and function. Annual Review of Biochemistry 50, 465-495.
75. Ragni G, Vegetti W, Riccaboni A et al. 2005 Comparison of GnRH agonists and antagonists in assisted reproduction cycles of patients at high risk of ovarian hyperstimulation syndrome. Human Reproduction 20, 2421-2425.
76. Romeu A, Balasch J, Ruiz Balda JA et al. 2003 Cost-effectiveness of recombinant versus urinary follicle-stimulating hormone in assisted reproduction techniques in the Spanish public health care system. Journal of Assisted Reproduction and Genetics 20, 294-300.
77. Rongieres-Bertrand C, Olivennes F, Righini C et al. 1999 Revival of the natural cycles in in-vitro fertilization with the use of a new gonadotrophin-releasing hormone antagonist (Cetrorelix): a pilot study with minimal stimulation. Human Reproduction 14, 683-688.
78. Ruman JI, Pollak S, Trousdale RK et al. 2005 Effects of long-acting recombinant human follicle-stimulating hormone analogs containing N-linked glycosylation on murine folliculogenesis. Fertility and Sterility 83 (Suppl. 1), 1303-1309.
79. Steelman SL, Pohley FM 1953 Assay of the follicle stimulating hormone based on the augmentation with human chorionic gonadotropin. Endocrinology 53, 604-616.
80. Sudo S, Kudo M, Wada S et al. 2002 Genetic and functional analyses of polymorphisms in the human FSH receptor gene. Molecular Human Reproduction 8, 893-899.
81. Sullivan MW, Stewart-Akers A, Krasnow JS et al. 1999 Ovarian responses in women to recombinant follicle-stimulating hormone and luteinizing hormone (LH): a role for LH in the final stages of follicular maturation. Journal of Clinical Endocrinology and Metabolism 84, 228-232.
82. Timossi CM, Barrios-de-Tomasi J, Gonzalez-Suarez R et al. 2000 Differential effects of the charge variants of human follicle-stimulating hormone. Journal of Endocrinology 165, 193-205.
83. Touraine P, Beau I, Gougeon A et al. 1999 New natural inactivating mutations of the follicle-stimulating hormone receptor: correlations between receptor function and phenotype. Molecular Endocrinology 13, 1844-1854.
84. Ulloa-Aguirre A, Timossi C 2000 Biochemical and functional aspects of gonadotrophin-releasing hormone and gonadotrophins. Reproductive BioMedicine Online 1, 48-62.
85. Ulloa-Aguire A, Timossi C, Barrios-de-Tomasi J et al. 2003 Impact of carbohydrate heterogeneity in function of follicle-stimulating hormone: studies derived from in vitro and in vivo models. Biology of Reproduction 69, 379-389.
86. Ulloa-Aguirre A, Timossi C, Mendez JP 2001 Is there any physiological role for gonadotrophin oligosaccharide heterogeneity in humans? I. Gondatrophins are synthesized and released in multiple molecular forms. A matter of fact. Human Reproduction 16, 599-604.
87. Ulloa-Aguire A, Timossi C, Damian-Matsumura P, Dias JA 1999 Role of glycosylation in function of follicle-stimulating hormone. Endocrine 11, 205-215.
88. Ulloa-Aguirre A, Midgley AR Jr, Beitins IZ, Padmanabhan V 1995 Follicle-stimulating isohormones: characterization and physiological relevance. Endocrine Reviews 16, 765-787.
89. Ulloa-Aguirre A, Damian-Matsumura P, Jimenez M et al. 1992 Biological characterization of the isoforms of urinary human follicle-stimulating hormone contained in a purified commercial preparation. Human Reproduction 7, 1371-1378.
90. van Wely M, Westergaard LG, Bossuyt PM et al. 2003 Effectiveness of human menopausal gonadotropin versus recombinant follicle-stimulating hormone for controlled ovarian hyperstimulation in assisted reproductive cycles: a meta-analysis. Fertility and Sterility 80, 1086-1093.
91. Watkins PC, Eddy R, Beck AK 1987 DNA sequence and regional assignment of the human follicle-stimulating hormone beta-subunit gene to the short arm of human chromosome 11. DNA 6, 205-212.
92. Watkins P, Eddy R, Beck A et al. 1985 Assignment of the human gene for the beta subunit of follicle stimulating hormone (FSHB) to chromosome 11 (Abstract). Cytogenetics and Cell Genetics 40, 773.
93. Weenen C, Pena JE, Pollak SV et al. 2004 Long-acting follicle-stimulating hormone analogs containing N-linked glycosylation exhibited increased bioactivity compared with O-linked analogs in female rats. Journal of Clinical Endocrinology and Metabolism 89, 5204-5212.
94. Whittemore AS, Harris R, Itnyre J 1992 Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group. American Journal of Epidemiology 136, 1184-1203.
95. Wide L 1989 Follicle-stimulating hormones in anterior pituitary glands from children and adults differ in relation to sex and age. Journal of Endocrinology 123, 519-529.
96. Wide L 1986 The regulation of metabolic clearance rate of human FSH in mice by variation of the molecular structure of the hormone. Acta Endocrinologica (Copenhagen) 112, 336-344.
97. Wide L 1985 Median charge and charge heterogeneity of human pituitary FSH, LH and TSH. II. Relationship to sex and age. Acta Endocrinologica (Copenhagen) 109, 190-197.
98. Willis DS, Watson H, Mason HD et al. 1998 Premature response to luteinizing hormone of granulosa cells from anovulatory women with polycystic ovary syndrome: relevance to mechanism of anovulation. Journal of Clinical Endocrinology and Metabolism 83, 3984-3991.
99. Yeko T, Pasqualini SR, Alam V, Tredway D 2004 Cumulative ovulation and pregnancy rates according to recombinant human follicle stimulating hormone r-hFSH dosing: comparison of a new formulation of follitropin alpha in vials versus the standard formulation of follitropin alpha in ampoules. Fertility and Sterility 82, S119.
100. Zambrano E, Barrios-de-Tomasi J, Cardenas M, Ulloa-Aguirre A 1996 Studies on the relative in-vitro biological potency of the naturally-occurring isoforms of intrapituitary follicle stimulating hormone. Molecular Human Reproduction 2, 563-571.
101. Zambrano E, Olivares A, Mendez JP et al. 1995 Dynamics of basal and gonadotropin-releasing hormone-releasable serum follicle-stimulating hormone charge isoform distribution throughout the human menstrual cycle. Journal of Clinical Endocrinology and Metabolism 80, 1647-1656.
102. Zeleznik AJ 2004 The physiology of follicle selection. Reproductive Biology and Endocrinology 2, 31-37.
103. Zeleznik AJ, Hillier SG 1984 The role of gonadotropins in the selection of the pre-ovulatory follicle. Clinical Obstetrics and Gynecology 27, 927-940.
104. Zeleznik AJ, Schuler HM, Reichert LE Jr 1981 Gonadotropin-binding sites in the rhesus monkey ovary: role of the vasculature in the selective distribution of human chorionic gonadotropin to the pre-ovulatory follicle. Endocrinology 109, 356-362.